K. Zaman

Discipline

Psychology (6) Sociology (2) Communication sciences (2) Economies and finances (2)

Type

Articles (56) Reviews (14) Conferences and symposiums (4) Thesis (1)

Co-author

Date

Source

Keyword

Cancer (47) cancer (46) Cancer (46) Patients (44) Patients (43) Breast (42) Treatment (38) Human beings (30) therapy (24) Therapeutics (24) Chemotherapy (21) Chemotherapy (21) disease (18) trial (18) Cancer--Patients (18) disease (18) survival (17) Survival (17) Use (15) Control (14) toxicity (13) oncology (13) Oncology (13) Toxicology (13) Management (12) Inhibitors (11) Tumors (11) quality of life (10) rate (10) Development (10)

Documents written by K. Zaman (61) | is about K. Zaman (0)

PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells.
M. Morotti et al.
Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study.
N. Harbeck et al.
Oncologie: ce qui a changé en 2023 [Oncology: what's new in 2023]
J. Jankovic et al. (Jan 17, 2024)
Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer.
V. Guarneri et al. (2024)
Response of Brain and Meningeal Metastases to Trastuzumab-Deruxtecan in a Patient with HER2-Low Breast Cancer: A Case Report.
B. Wolf et al.
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study.
R. Kristeleit et al.
Elevated liver function tests in a patient with breast cancer.
C. Neftel et al.
A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer.
C. Mamot et al. (Mar 6, 2023)
Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study.
C. Bandiera et al. (Jan 3, 2023)
Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project.
M.E. Cazzaniga et al. (2023)
Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14].
A. Mueller et al.
Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer.
M. Aapro et al.
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer.
F. Schettini et al.
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study.
V. Boni et al.
Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer.
P. Courlet et al. (Jun 21, 2022)
Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor.
V. Scabia et al. (Jun 6, 2022)
Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force.
E. Razis et al.
Effets indésirables des nouvelles thérapies du cancer du sein : quand faut-il réagir ? [Adverse effects of new breast cancer therapies : when to react ?]
N. Dris et al. (May 18, 2022)
Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA).
M. Joerger et al. (Apr 27, 2022)
Oncologie [2021 Oncology update]
M.L. Meyer et al. (Feb 2, 2022)
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.
F.G. Herrera et al.
Diabète secondaire aux nouvelles thérapies ciblées contre le cancer [New-onset diabetes and novel targeted therapies against cancer]
A. Zordan et al. (Jun 2, 2021)
Cancer du sein chez la femme en [Breast cancer during pregnancy]
M. Schnetz et al. (May 19, 2021)
Oncologie [2020 oncology update]
G. Dei Tos et al. (Jan 27, 2021)
Optimizing oral targeted anticancer therapies study for patients with solid cancer: Protocol for a randomized controlled medication adherence program along with systematic collection and modeling of pharmacokinetic and pharmacodynamic data.
C. Bandiera et al. (2021)

next